Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Post-traumatic Stress Disorder01:27

Post-traumatic Stress Disorder

475
Post-traumatic stress disorder (PTSD) is a psychiatric condition that arises following exposure to traumatic events such as natural disasters, forced displacement, or severe accidents. It significantly impairs individuals' ability to cope with daily activities and disrupts their emotional and psychological equilibrium.
Symptoms and Behavioral Manifestations
A spectrum of distressing symptoms characterizes PTSD. Recurrent flashbacks, where individuals involuntarily relive traumatic events,...
475
Treatment Strategies for Psychological Disorders01:24

Treatment Strategies for Psychological Disorders

721
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
721
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

864
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
864
Social Anxiety Disorder01:28

Social Anxiety Disorder

436
Social anxiety disorder, also known as social phobia, is characterized by an intense fear of social situations where one might face humiliation, rejection, embarrassment, or negative evaluation. This disorder leads individuals to avoid activities like casual conversations, public speaking, or seemingly simple tasks such as eating, signing documents, or swimming, in public settings. Its impact extends beyond discomfort, often significantly interfering with daily functioning and quality of life.
436
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

457
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
457
Panic Disorder01:27

Panic Disorder

621
Panic disorder is an anxiety disorder characterized by recurrent and sudden minutes-long episodes of intense fear, known as panic attacks. These attacks may feel like heart attacks and often happen without warning or a specific cause. They can include symptoms such as rapid heart rate, shortness of breath, chest pain, trembling, sweating, dizziness, and a sense of helplessness. During a panic attack, individuals may feel as though they are experiencing a heart attack or are in a...
621

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sex-specific associations between potentially traumatic events and cardiovascular disease in middle-aged and older adults.

Journal of traumatic stress·2026
Same author

Personalizing Suicide Risk Assessment: Machine Learning Extraction of Cross-Modal Interactions Between Psychosocial and Demographic Factors in Veterans <sup>1</sup>.

medRxiv : the preprint server for health sciences·2026
Same author

Comparative Evaluation of Pretrained Large Language Models for Suicide Risk Prediction from Clinical Notes in U.S. Veterans.

medRxiv : the preprint server for health sciences·2026
Same author

Characteristics of Rural Veterans Using VA Video-to-Home Telehealth or Community Care Network for Mental Healthcare.

Psychiatric research and clinical practice·2026
Same author

Developing a Natural Language Processing Strategy to Avoid Biased Data in Electronic Health Record Suicide Risk Modeling.

Psychiatric research and clinical practice·2026
Same author

Suicide Prevention RCT Pilot: Rural Veterans Receiving Mental Health Community Care.

Rural mental health·2026

Related Experiment Video

Updated: Jan 15, 2026

Simultaneous Application of Transcranial Direct Current Stimulation during Virtual Reality Exposure
08:20

Simultaneous Application of Transcranial Direct Current Stimulation during Virtual Reality Exposure

Published on: January 18, 2021

4.4K

Glecaprevir/Pibrentasvir for Post Traumatic Stress Disorder.

Bradley V Watts1, Jessica E Hoyt2, Krista D Disano3

  • 1Watts, MD, MPH, Larner College of Medicine at the University of Vermont, Burlington VT; White River Junction VA Medical Center, White River Junction VT; VA Office of Rural Health, White River Junction VT.

Psychopharmacology Bulletin
|January 14, 2026
PubMed
Summary

Glecaprevir/Pibrentasvir (GLE/PIB) shows promise in reducing Posttraumatic Stress Disorder (PTSD) symptoms and may modulate inflammation. Further research is needed to confirm these findings for PTSD treatment.

Keywords:
PTSDclinical trialglecaprevir/pibrentasvirinflammationinterleukinspsychopharmacology

More Related Videos

Stress-Enhanced Fear Learning, a Robust Rodent Model of Post-Traumatic Stress Disorder
05:49

Stress-Enhanced Fear Learning, a Robust Rodent Model of Post-Traumatic Stress Disorder

Published on: October 13, 2018

12.7K
Rapid Fractionation and Isolation of Whole Blood Components in Samples Obtained from a Community-based Setting
11:31

Rapid Fractionation and Isolation of Whole Blood Components in Samples Obtained from a Community-based Setting

Published on: November 30, 2015

16.5K

Related Experiment Videos

Last Updated: Jan 15, 2026

Simultaneous Application of Transcranial Direct Current Stimulation during Virtual Reality Exposure
08:20

Simultaneous Application of Transcranial Direct Current Stimulation during Virtual Reality Exposure

Published on: January 18, 2021

4.4K
Stress-Enhanced Fear Learning, a Robust Rodent Model of Post-Traumatic Stress Disorder
05:49

Stress-Enhanced Fear Learning, a Robust Rodent Model of Post-Traumatic Stress Disorder

Published on: October 13, 2018

12.7K
Rapid Fractionation and Isolation of Whole Blood Components in Samples Obtained from a Community-based Setting
11:31

Rapid Fractionation and Isolation of Whole Blood Components in Samples Obtained from a Community-based Setting

Published on: November 30, 2015

16.5K

Area of Science:

  • Psychiatry
  • Pharmacology
  • Immunology

Background:

  • Posttraumatic Stress Disorder (PTSD) is a prevalent mental health condition with limited effective pharmacological treatments.
  • Glecaprevir/Pibrentasvir (GLE/PIB), an antiviral medication for Hepatitis C Virus (HCV), has shown potential in preliminary studies for PTSD treatment.
  • The role of inflammation in PTSD pathogenesis suggests potential therapeutic targets.

Purpose of the Study:

  • To investigate the efficacy of GLE/PIB in reducing PTSD symptoms.
  • To explore the impact of GLE/PIB treatment on inflammatory biomarkers in veterans with PTSD.
  • To assess the safety and tolerability of GLE/PIB for PTSD treatment.

Main Methods:

  • An open-label, uncontrolled trial was conducted with ten US veterans diagnosed with PTSD and without HCV infection.
  • Participants received GLE/PIB (100 mg/40 mg) daily for 8 weeks.
  • PTSD symptoms were assessed using the Clinician Administered PTSD Scale for DSM 5 (CAPS-5), with follow-ups at 3 and 6 months. Serum inflammatory biomarkers were analyzed at baseline and post-treatment.

Main Results:

  • GLE/PIB treatment resulted in a significant reduction in PTSD symptoms, with large effect sizes observed at 6-month follow-up (CAPS-5: d = 1.6, p < 0.01).
  • Eight participants achieved treatment response, with six meeting criteria for total PTSD remission (CAPS-5 score < 12).
  • Lower baseline interleukin-27 (IL-27) levels predicted treatment response, and changes in IL-9 levels during treatment correlated with symptom improvement.

Conclusions:

  • GLE/PIB demonstrates potential as an effective treatment for PTSD, significantly improving symptoms and achieving remission in a subset of patients.
  • The treatment may modulate inflammatory responses associated with PTSD, as indicated by changes in IL-27 and IL-9 levels.
  • Further rigorous clinical trials are warranted to confirm the efficacy and mechanisms of GLE/PIB in PTSD management and its impact on inflammation.